GSK partners with Engitix on liver fibrosis regression using human extracellular matrix platform, up to USD 59.4m upfront

GSK has entered a research collaboration and option agreement with UK-based Engitix Ltd paying up to GBP 44.5 million (USD 59.4 million) in upfront and near-term payments to access a largely unexplored area of liver disease biology: the mechanisms that allow established fibrosis to regress. The collaboration is focused on liver fibrosis and structured around Engitix's proprietary human extracellular matrix platform, which generates target hypotheses from human-derived liver tissue rather than animal models. Under the option agreement, GSK can license assays, datasets, and validated targets arising from the work and will lead all subsequent development and commercialization. Engitix is eligible to receive up to GBP 118 million (USD 157.5 million) per target in downstream milestone payments, plus tiered low-single-digit royalties on future product sales.

The deal is pre-asset: no named drug candidates exist at signing. Engitix will generate human ECM-based disease models and high-resolution multi-omics datasets focused specifically on mechanisms of fibrosis resolution — a biologically distinct problem from fibrosis prevention that has attracted comparatively little drug discovery investment. The collaboration remains several years removed from the clinic, with no disclosed targets or development candidates.

Deal context

Engitix, a spinout from University College London's Institute for Liver and Digestive Health, built its ECM platform around a proprietary bioarchive of human liver tissue collected across different stages of disease to identify molecular drivers of fibrosis regression. The company argues that human-derived extracellular matrix data may provide more clinically relevant targets than conventional animal models.

The scientific focus on fibrosis regression rather than progression is mechanistically significant. Most approved and late-stage investigational therapies in liver disease — including resmetirom, approved by the US FDA in 2024 for MASH with fibrosis — are designed to halt or slow fibrosis, not reverse established scarring. The ECM remodeling biology underlying regression is poorly characterized and has generated few validated drug targets, which is the gap Engitix's platform is designed to address. Most current fibrosis programs focus on metabolic, inflammatory, or hepatocyte-directed pathways, whereas Engitix is attempting to discover targets within extracellular matrix remodeling itself.

Engitix has prior partnerships with Takeda, including a collaboration on IBD fibrosis announced in 2022 valued at up to USD 300 million in milestones, and a separate arrangement with Dompé Farmaceutici. No Engitix-originated compound has yet entered clinical trials; the platform remains a target-generation engine whose outputs are prosecuted by partners.

GSK's other BD activity in the fibrosis and inflammatory disease space include the November 2025 signing of feasibility agreements with Flagship Pioneering's ProFound Therapeutics and Quotient Therapeutics to discover and validate novel targets in respiratory and liver diseases, including MASH, under a broader framework collaboration with Flagship. That arrangement similarly gave GSK the option to progress programs into clinical studies following preclinical validation — a structure that minimizes upfront capital commitment while preserving access to differentiated biology.

---

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

---

Spot something wrong? Report an issue with this article